ELISA for Azadirachtins
J. Agric. Food Chem., Vol. 45, No. 6, 1997 2365
Preparation of the Activated 3-Hemisuccinylazadirachtin
(4b). Dry (5 h, 0.03 Torr) 3b (16 mg) was treated analogously
to the preparation procedure of 3a . The solvent was evapo-
rated in a stream of nitrogen to yield 27 mg of a pale yellow
solid that showed one additional spot in the analytical TLC
with Rf ) 0.72 (solvent system 1). Preparative TLC yielded
10 mg (56% with respect to 3b) of 4b, a white solid. The
unstable and highly moisture sensitive compound was used
immediately for further synthesis.
repeated every 4 weeks. Animals were bled (2-5 mL) 10 days
after each boost from the central ear artery under light
anesthesia. All procedures, except for the preparation of the
immunogens, were carried out by personnel of the Laboratory
Animal Health Clinic at the University of California at Davis.
The blood was kept overnight at 4 °C to allow clotting. After
centrifugation (500g, 10 min), removal of the clot, and a second
centrifugation (500g, 10 min), the clear serum was carefully
removed with
a Pasteur pipet, aliquoted, and stored in
cryovials at -20 °C.
Preparation of the BSA Conjugates. These reactions were
conducted in 5-mL glass flasks containing magnetic stirring
bars. BSA (fraction V, 96-99%) was dissolved (10 mg) in 2
mL of 0.2 M borate buffer, and 0.2 mL of dimethylformamide
(DMF) was added very slowly (ca. 15 min) with rigorous
stirring at room temperature, causing a slight precipitation.
A solution of 5 mg of active ester (3a or 4b) in 0.2 mL of
anhydrous DMF was added slowly (ca. 20 min). A small
amount of precipitate developed during this addition. The
mixture was stirred gently overnight on ice and then dialyzed
versus 0.2 M PBS (five changes of 2 L each, 5 days, at room
temperature) in a SpectraPor membrane (6000-8000 MW
cutoff) to desorb and separate hapten molecules that were
bound to the protein by physisorption only. The dialyzed
solution was transferred into polypropylene vials and stored
at -30 °C.
Scr een in g of An tiser a w ith Tw o-Dim en sion a l Titr a -
tion . For the determination of initial titers of each serum, a
microtiter plate (Nunc) was coated with 100 µL/well of a
dilution series of coating antigen (0.016-2 µg/mL) and an
additional row with an indifferent fenvalerate-conjugated BSA
antigen (2 µg/mL) in 0.5 M carbonate buffer (pH 8.5). Plates
were sealed with adhesive plate sealers and incubated over-
night at 4 °C. The following day, the coated plates were
washed three times with PBST. Diluted serum (100 µL/well)
was added to each well and incubated for 2 h at room
temperature. The sera were checked in a two-dimensional
titration dilution series (1:500 to 1:256000 and two controls
containing a fenvalerate antiserum 1:20000 in 0.2 M PBS, pH
7.5) against the dilution series of coating antigens. After
another washing step, 100 µL/well of goat anti-rabbit IgG
conjugated to horseradish peroxidase (HRP; GAR/HRP), di-
luted 1:8000 in 0.2 M PBS, pH 7.5, was added and incubated
for 2 h at room temperature. The plates were washed again,
and 100 µL/well of substrate solution [800 µL of a 1.2%
3,3′,5,5′-tetramethylbenzidine (TMB) in DMSO and 13.2 µL
of 30% H2O2 in 100 mL of a 0.1 M acetate buffer, pH 5.5] was
added. After 10-20 min, the enzyme reaction was stopped
with 50 µL/well of 4 M H2SO4. The absorbance was read at
450-650 nm.
Preparation of the KLH Conjugates. The reactions were
conducted analogous to the preparation of BSA conjugates.
Precipitate developed during the addition of the active ester
(3a or 4b). The dialyzed solution was transferred into
polypropylene vials and stored at -30 °C.
Preparation of Tyramine Derivatives. The reaction was
conducted in a 5-mL glass flask containing a magnetic Teflon
stirring bar. Tyramine hydrochloride (99%), 10 mg, was
dissolved in 2 mL of 0.2 M borate buffer. DMF (0.2 mL) was
added very slowly (ca. 15 min) during rigorous stirring at room
temperature, causing a slight precipitation. The active ester
(3a or 4b) was dissolved (5 mg) in 0.2 mL of anhydrous DMF
and added very slowly (ca. 20 min). A slight precipitate
developed during this addition. The solution was stirred
gently overnight on ice, and the solvent was subsequently
evaporated (24 h, 0.03 Torr). The residue was redissolved in
2-propanol and subjected to preparative TLC with Rf ) 0.22
(solvent system 2, toluene/1-propanol, 5:1), yielding 1.4 mg
(25% with respect to the active ester) of the 7-hemisuccinyl-
azadirachtin-tyramine derivative. The yield of the 3-hemisuc-
cinylazadirachtin-tyramine derivative was only 0.8 mg (14%
with respect to the active ester). Therefore, the similar Rf
value on TLC examination with Rf ) 0.23 (solvent system 2)
was considered as tentative identification; 7-hemisuccinylaza-
dirachtin-tyramine was characterized by NMR and MS: 1H
NMR (CDCl3) δ 7.05 (m, 4H, aromatic), 6.90 (dq, J d ) 1.0 Hz,
J q ) 7.0 Hz, 1H, 3′), 6.82 (dd, J ) 2.1, 9 Hz, 4H, 7′), 6.60 (br,
1H, NH), 6.46 (d, J ) 2.9 Hz, 1H, 23), 5.65 (s, 1H, 21), 5.05 (d,
J ) 2.9 Hz, 1H, 22), 5.02 (s, 1H, 11-OH), 4.76 (s, 1H, 7), 4.65
(d, J ) 3.3 Hz, 1H, 15), 4.61 (dd, J ) 2.4, 12.6 Hz, 1H, 6), 4.17
(d, J ) 9.5 Hz, 1H, 19a), 4.05 (d, J ) 8.9 Hz, 1H, 28b), 3.76 (s,
3H, methyl ester), 3.68 (s, 3H, methyl ester), 3.64 (d, J ) 9.8
Hz, 1H, 19b), 3.30 (d, J ) 12.4 Hz, 2H, 5, 9), 3.2 (br, 1H,
tyramine-OH) 2.9 (br, 1H, 20-OH), 2.37 (d, J ) 5.2 Hz, 1H,
17), 2.03 (s, 3H, 18), 1.85 (s, 3H, 5′), 1.78 (d, J ) 7.0 Hz, 3H,
4′), 1.75 (s, 3H, 30); EI-MS (70 eV), m/e (rel intensity) 95 (90),
105 (100), 120 (65), 143 (23), 151 (54), 195 (4.5), 229 (4.0), 277
(3.1), 347 (3.4), 403 (2.1), 475 (1.8), 507 (1.3), 521 (1.2), 535
(1.4), 545 (1.3), 559 (3.7), 595 (9.5), 588 (1.1), 620 (0.8), 661
(0.3), 704 (0.4), 719 (0.1) (no parent ion at 955).
ELISA Coa tin g An tigen F or m a t. Com p etition . To
determine the analytical characteristics of the ELISA coating
antigen format for each serum, one microtiter plate was
divided into two equal (12 columns, 3 rows) parts and one
unequal (12 columns, 2 rows) part. The equal parts were
coated with 100 µL/well of the two coating antigens 2a -BSA
and 3b-BSA, and the unequal part was coated with
a
fenvalerate-BSA conjugate as a protein control, with the
optimized concentrations (0.03 µg/mL 2a -BSA, 1 µg/mL 3b-
BSA, 1 µg/mL fenvalerate-BSA) overnight at 4 °C. The next
day, the coated plates were washed three times with PBST
and the analyte (0.0013-100 µg/mL in 0.2 M PBS, pH 7.5, 50
µL/well) and 50 µL/well of the optimized dilution of the
antiserum (no. 7053 or 7056, 1:20000; no. 7052 or 7054,
1:100000 in 0.2 M PBS, pH 7.5) were added and incubated for
2 h at room temperature. After another washing step, 100
µL/well of GAR/HRP, diluted 1:8000 in 0.2 M PBS, pH 7.5,
was added and incubated for 1 h at room temperature. The
plates were washed again, and 100 µL/well of substrate
solution was added; after 10-20 min, the enzyme reaction was
stopped with 50 µL/well 4 M H2SO4. The absorbance was read
at 450-650 nm.
RESULTS AND DISCUSSION
Ha p ten Syn th esis. Since antibodies recognize best
the part of the hapten that is most distant from the
conjugate linkage, a carboxylic group opposite from the
most characteristic groups of the molecule was desir-
able. However, the complex structure of azadirachtin
with a densely packed array of oxygen functionalities
of many different types made it difficult to determine
which portions of the molecule are most unique. In the
course of studies on azadirachtin, it was determined
(Simmonds et al., 1995a) that there is not much change
in the biological activity of azadirachtin when the acyl
groups attached to the 1- and 3-hydroxys are modified
or removed. It is known from extensive synthetic work
(Grossmann and Ley, 1994) on azadirachtin that the
3-hydroxy group of azadirachtin is readily saponified
Im m u n iza tion of Ra bbits. Rabbits (female New Zealand,
white, 3-5 kg) 7052 and 7054 were immunized with 2a -KLH,
and rabbits 7053 and 7056 were immunized with 3b-KLH.
Rabbits were injected intradermally (5-20 sites per animal)
with 100 µg of the corresponding hapten-protein conjugate.
For injection, the immunogens were dissolved in 0.9% sterile
NaCl solution and mixed 1:1 with Freund’s complete adjuvant
to a final volume of 500 µL/injection. For the boost immuniza-
tion, the immunogens were prepared in the same way except
Freund’s incomplete adjuvant was used. The boosting was
started 1 month after the initial immunization and was